
This is the author’s final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

http://eprints.gla.ac.uk/173985/

Deposited on: 17 January 2019
Diagnosis of non-effusive feline infectious peritonitis by reverse transcriptase quantitative polymerase chain reaction from mesenteric lymph node fine-needle aspirates

Dawn Dunbar¹, Wendy Kwok³, Elizabeth Graham¹, Andy Armitage², Richard Irvine¹, Pamela Johnston¹, Michael McDonald¹, Dorothy Montgomery, Lesley Nicolson¹, Elise Robertson⁴, William Weir¹, Diane D. Addie¹*

¹ Veterinary Diagnostic Services, School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Bearsden Road, Glasgow, G61 1QH

² Greenside Veterinary Practice Ltd, Greenside Farm, St Boswells, TD6 0AJ

³ Department of Infectious Diseases and Public Health, College of Veterinary Medicine and Life Sciences, City University of Hong Kong

⁴ Feline Vet Ltd, New Priory Veterinary Surgery, Brighton, East Sussex, BN34QN, UK
* Corresponding author: Diane D. Addie, PhD, BVMS, MRCVS

Veterinary Diagnostic Services, School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Bearsden, Glasgow, G61 1QH, UK

Tel: +33 (0) 559 286253

Email: draddie@catvirus.com

Keywords: feline infectious peritonitis, coronavirus, polymerase chain reaction, RT-PCR, mesenteric lymph node, fine-needle aspirate, non-effusive FIP, diagnosis, biopsy
Abstract

Objectives: The aim of this study was to evaluate feline coronavirus (FCoV) reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) on fine-needle aspirates (FNA) from mesenteric lymph nodes (MLN) collected in sterile saline for the purpose of diagnosing non-effusive feline infectious peritonitis (FIP) in cats.

Methods: First, the ability of the assay to detect viral RNA in MLN FNA preparations compared to MLN biopsy preparations was assessed in matched samples from eight cats. Secondly, a panel of MLN FNA samples was collected from a series of cats representing non-effusive FIP cases (n = 20), FCoV seropositive individuals (n = 8) and FCoV seronegative individuals (n = 18). Disease status of animals was determined using a combination of gross pathology, histopathology and/or ‘FIP profile’ consisting of serology, clinical pathology and clinical signs.

Results: Viral RNA was detected in 18 of 20 non-effusive FIP cases; it was not detected in two cases that presented with neurological FIP. Samples from 18 seronegative non-FIP control cats and seven of eight samples from seropositive non-FIP control cats contained no detectable viral RNA. Thus, as a method for diagnosing non-effusive FIP, MLN FNA RT-qPCR had an overall sensitivity of 90.0 % and specificity of 96.1 %.

Conclusions and relevance: In cases with a high index of suspicion of disease, RT-qPCR targeting FCoV in MLN FNA can provide important information to support the ante-mortem diagnosis of non-effusive FIP. Importantly, viral RNA can be reliably detected in MLN FNA samples in saline submitted via the national mail service. When applied in combination with biochemistry, haematology and serological tests in
cases with a high index of suspicion of disease, the results of this assay may be used to support a diagnosis of non-effusive FIP.
Feline coronavirus (FCoV) is an alpha-coronavirus that is ubiquitous among populations of felidae. FCoV and other viruses within this family are associated with enteric disease, such as ferret coronavirus, canine coronavirus and transmissible gastroenteritis virus of pigs. In addition to its primarily enteric pathogenesis, FCoV is associated with a progressive disease named feline infectious peritonitis (FIP). In the majority of cases, FCoV infection is not accompanied by overt clinical signs. A proportion of cats exposed to the virus exhibit signs of mild enteric disease, usually manifesting as transient diarrhoea, sometimes with vomiting. In around 5% of cases, the virus elicits an aberrant immune response in the host resulting in an almost invariably lethal pyogranulomatous perivasculitis, a consequence of extravasation of FCoV-infected monocytes. FIP is considered to consist of a spectrum of presentations, with an effusive form at one end and a non-effusive form at the other.

In recent years, great strides have been made in the diagnosis of effusive FIP. Collection of effusion samples from the body cavities is a minimally invasive veterinary intervention. Recent studies have shown that the detection of FCoV by RT-qPCR, using template RNA from the effusion is highly supportive of a diagnosis of effusive FIP, although two recent studies did find low amounts of FCoV RNA in effusions of one of 29, and one of 47 cats in their control groups of cats without FIP. However, as a minimally invasive sampling technique has not been described for non-effusive FIP, confirmation is often achieved only at the time of post-mortem. A major difficulty in the diagnosis of FIP is the vast and variable range of clinical signs associated with the disease. Although haematological, biochemical and serological parameters may be measured to provide an index of suspicion of FIP; these cannot be used to confirm a diagnosis.
Cats are frequently subjected to invasive biopsy procedures, which often do not result in a conclusive diagnosis. Kipar et al.\textsuperscript{12} described one manifestation of non-effusive FIP primarily presenting as enlargement of the mesenteric lymph nodes (MLN), similar to a manifestation of coronavirus-induced pyogranulomatosis reported in the ferret\textsuperscript{13}, and frequently mistaken for tumours in both species\textsuperscript{12,14}. In one study, pyogranulomatous lesions were found in the MLNs in eight (33\%) of 24 cats with FIP\textsuperscript{15} while in another, mesenteric lymphadenopathy was noted by ultrasound in nine of 16 cats with FIP\textsuperscript{16}. It should be appreciated that other conditions, such as toxoplasmosis, can also present with enlarged mesenteric lymph nodes\textsuperscript{17}.

Histopathological identification of FIP lesions in biopsies is currently the only method to confirm a diagnosis of non-effusive FIP. However, histopathology of the lymph node in FIP can reveal non-specific pyogranulomatous inflammation, which has many possible causes. In such cases, immunohistochemistry (IHC) to detect FCoV-specific proteins may be performed. The reliability of IHC depends on the specificity of the assay. A poorly designed assay, such as one with no negative control antibody run for every section of tissue on which the anti-FCoV antibody is run, will fail to identify non-specific adherence of antibodies to some feline tissues, causing false positive results (unpublished observation). IHC can also lack sensitivity, as it depends on the surgeon submitting an area of the organ in which virus-infected cells were present. In non-effusive FIP there may be few lesions and in order to obtain an accurate biopsy an exploratory laparotomy is usually required. Laparotomy for the collection of biopsy material is an invasive, potentially stressful and risk-associated intervention, which may adversely affect an already sick cat where FIP is suspected. It has been shown that cats with FIP often have a history of stress\textsuperscript{18,19} although it is unknown whether experiencing further stress after FIP has developed affects the outcome.
Moreover, immunosuppressive doses of corticosteroids, routinely used for FIP treatment, are contra-indicated in cats that have undergone recent surgery, as they hamper the healing process. In contrast, ultrasound-guided collection of fine-needle aspirate material is a far less invasive procedure.

The detection of viral ribonucleic acid (RNA) in faeces or blood or the detection of anti-FCoV antibodies in the blood is not diagnostic of FIP. Combinations of all three findings may be present in FCoV-infected cats which are healthy, or which are sick due to non-FIP diseases. As a considerable proportion of the feline population may be positive for FCoV antibodies, up to 26% in the UK, a major challenge for the clinician is the diagnosis of FIP in the FCoV seropositive cat where the presence of antibodies may either be incidental or may be associated with FIP. The predictive value of a negative FCoV antibody test for ruling out FIP has been calculated as 97% and therefore a seronegative result usually excludes FIP provided that a sufficiently low initial serum dilution is used, such as 1:20.

Previous studies have shown results consistent with a diagnosis of non-effusive FIP can be observed through microscopic examination of smear preparations from FNAs or Tru-cut biopsies of the liver and/or kidney. However, in many cases such samples provide inadequate material for analysis due to the destruction of cellular morphology, thus reducing test sensitivity. We hypothesised that the problem of cellular damage could be avoided by using reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) to detect FCoV in FNA samples derived from MLN. Such a technique has the potential to be a minimally invasive diagnostic test for non-effusive FIP. The aim of the present study, therefore, was to evaluate the diagnostic potential of MLN FNAs combined with FCoV RT-qPCR. As an initial step, the sensitivity of this method was compared to RT-qPCR of MLN biopsies.
In a prospective study, the specificity of MLN FNA FCoV RT-qPCR was then analysed using samples from groups of cats that were (a) FCoV seronegative, (b) seropositive but without signs indicative of FIP (or had confirmation of other diseases/causes of death) and (c) FIP cases. MLN FNA samples submitted to the Veterinary Diagnostic Service at the University of Glasgow were also evaluated to determine if non-preserved (i.e. saline) samples submitted from field clinics would be suitable, thereby assessing if transit to the laboratory adversely affected test sensitivity. A full assessment of the sensitivity, specificity and diagnostic accuracy of the method was performed.

MATERIALS AND METHODS

Sources of clinical samples

Samples from eight FIP cases were used for an initial study (Group T). The main study then included a group of twenty cats with non-effusive FIP (Group D), a control group of eight seropositive cats without FIP (Group P) and a second control group of eighteen seronegative cats (Group N) also without FIP; details of the source of samples for these three groups are provided in Table 1. A proportion of these samples (n = 25) was collected from cats in the post-mortem room at the School of Veterinary Medicine, University of Glasgow that had been submitted for post mortem from veterinary practices throughout the UK. The remainder of samples came directly from referring veterinary surgeons across the UK including MLN FNAs collected in vivo and submitted in a small amount of sterile saline in a plain tube (n = 13), MLNB material collected in vivo (n = 1) and MLNB collected post mortem (n = 7) by referring veterinary surgeon and submitted to the laboratory by first class post. Samples received in the laboratory were stored at 4 °C until processed. The time from
sample collection to processing ranged from 24 hours to 7 days, with most samples being processed between 48 and 72 hours post-collection.

**Preparation of samples**

**Collection of mesenteric lymph node biopsy material (MLNB)**

MLN biopsies were collected post mortem by the University of Glasgow post-mortem room pathologist (supplementary material 1) or in vivo by the submitting veterinary surgeon during exploratory laparotomy or post mortem. Samples were placed in sufficient sterile saline to cover the biopsy material for transit to the laboratory.

**Mesenteric lymph node fine-needle aspirates (MLN FNAs)**

MLN FNA samples were collected either in vivo at participating veterinary practices or in situ at the University of Glasgow during post-mortem examination or extra corpus in the laboratory from excised lymph nodes. In vivo MLN FNA samples collected by ultrasound guidance or at exploratory laparotomy were expelled into 0.2 - 0.5 mL sterile saline in plain tubes and then mailed to the laboratory by first-class post, without refrigeration. Post mortem samples were collected in situ using a 21-gauge needle and a 2 mL syringe, MLNB was also collected to be stored as backup. Extra corpus FNAs were performed on either MLNB or whole MLN collected ante mortem (n = 1) or during post-mortem examination (n = 7). Paired FNA samples were prepared using a 21-gauge needle and a 2 mL syringe; one was expelled into 0.5 mL sterile saline and the other expelled into 0.5 mL RNAlater (Ambion, Huntingdon, UK) to inactivate RNAses and maintain the integrity of RNA therein during long-term storage. FNAs collected into RNAlater and any remaining MLNB (approximately 0.5 cm cubed/ 0.5 mL RNAlater) were stored in our biobank.

**FIP diagnosis**
Diagnosis of FIP was confirmed by histopathology where suitable sample material was available. Sufficient blood and tissue samples for virology, clinical pathology and histopathology had been collected in these cases to acquire a diagnosis. Tissue samples for histopathology were collected in 10% formal saline, including MLN and one or more of the following: kidney, liver, lung, spleen, omentum and any others deemed relevant for diagnosis. Where histopathology was unavailable or inconclusive, FIP diagnosis was based on the laboratory testing steps of the European Advisory Board of Cat Diseases (ABCD) FIP diagnosis algorithm as performed under the VDS laboratory ‘non-effusive FIP profile’. This commercial test profile comprises the following suite of blood tests: FCoV antibody titre, alpha-1 acid glycoprotein (AGP) measurement, albumin:globulin ratio, haematocrit and lymphocyte count. In group D (non-effusive cases, n = 20), 10 cases were confirmed by histopathology/IHC, one by gross pathology and the remainder being highly suspected of FIP on the basis of FIP profile. In the control groups, FIP was ruled out by a combination of histopathology and gross post-mortem examination in the seropositive group (P) in 7 of 8 cats and in the seronegative group (N) in 17 of 18 cats. A negative FIP profile was used to rule out FIP in a single case in each of the control groups. (Table 1.)

**RNA extraction**

RNA extraction from both MLNB and MLN FNA samples was performed using the RNAqueous 4-PCR extraction kit (Ambion, Huntingdon, UK). All materials form part of the RNAqueous 4-PCR kit unless otherwise stated. All equipment was wiped with RNase ZAP (Ambion). Tubes and pipette tips (Sarstedt, Germany) were RNAse and DNAse free. MLNB samples were cut into portions not larger than 0.075 g, added to a gentleMACS M tube (Miltenyi Biotech, Bergisch Gladbach, Germany) with 700 µL
lysis buffer and homogenised by a gentleMACS Dissociator (Miltenyi). The M tube
was centrifuged at 1,000 rpm at 4°C, for 10 minutes to ensure all material was lysed
and this step was repeated if required. RNAse and DNAse free phosphate buffered
saline (PBS) solution (Sigma) at 4°C was added to the MLN FNA sample in saline
and centrifuged at 1,000 rpm at 4°C. The resulting supernatant was discarded and the
pellet resuspended in 250 µL lysis buffer. Lysed MLN and MLN FNA samples were
kept on ice at all times. The extractions were performed as per the manufacturer’s
instructions, followed by DNAse treatments to remove contaminating DNA. The
RNA extract was transferred to a 1.5 mL tube (Sarstedt, Germany) and stored at
minus 80°C. The RNA extract underwent quantification and quality analysis using a

Reverse-transcriptase real-time PCR

The quantitative FCoV RT-qPCR assay was modified from the method of Gut et al.26,
based on the conserved 3’ UTR region of the FCoV genome. This assay is capable of
detecting both type I and type II FCoV. RT-qPCR was performed using the
Superscript ® III Platinum ® One Step RT-PCR System (Invitrogen, Carlsbad, CA,
USA). Unless otherwise stated, reagents were sourced from Invitrogen (Carlsbad, CA,
USA). Primer and probe sequences are detailed in Table 2. Each reaction consisted of
nuclease free PCR-grade water (Hyclone, GE Healthcare Life Sciences, UK/Qiagen,
UK), reaction mix containing dNTPs, 500 nM FCoV forward primer (Eurofins MWG
Operon, Ebersberg, Germany), 1 µM FCoV reverse primer (Eurofins MWG Operon),
200 nM FCoV probe (Eurofins MWG Operon), 25 mM ROX passive reference dye
and Superscript Platinum III. 17 µL of master mix was loaded into each well of a 96
well plate (Applied Biosystems, Foster City, CA, USA) and 3 µL of RNA extract or
assay control was added as required. The plate was then centrifuged briefly to
eliminate air bubbles before RT-qPCR was performed using the 7500 RT-PCR System (Applied Biosystems). A reverse-transcriptase step was performed at 48°C for 30 minutes, followed by a denaturing step at 95°C for 2 minutes. Thereafter, 40 cycles consisting of 95°C for 15 seconds and 60°C for one minute were performed. Samples were run in duplicate; no samples were found to produce conflicting results. Samples in which an amplicon was not detected by the 40th cycle were deemed to be negative. The Ct value for each reaction was recorded, with a lower Ct value, resulting from greater template RNA in the reaction mixture. GAPDH RT-qPCR was also performed on each sample; this was particularly important for FCoV RNA negative samples to demonstrate that there was sufficient RNA in each reaction. The protocol was the same as that of the FCoV RT-qPCR described above, with the primers and probe substituted for GAPDH specific primers and probe (see Table 2).

**FCoV indirect immunofluorescent antibody test**

The FCoV indirect immunofluorescent antibody test (IFA) was performed as previously described.**Statistical analysis**

Fisher’s Exact test (two-tailed) and the Pearson correlation co-efficient (r) were calculated using the core “stats” package in R. Scatter plots were generated using “ggplot2” in R. Inter-rater agreement was determined using a 2x2 contingency table and the kappa statistic (κ) with 95% confidence intervals calculated using the “fmsb” package in R.

**RESULTS**

**Viability of MLN FNAs for FCoV qRT-PCR assays**
A panel of matched MLN FNAs and MLNBs was assembled from a total of eight cats with a confirmed diagnosis of FIP (T01-T08). The quantity of RNA recovered from FNA preparations varied between 3 and 199 ng/µl, while that recovered from the MLNB preparations varied between 178 and 1,855 ng/µl (supplementary material 1). On average, a 35-fold lower concentration of RNA was recovered by FNA than by MLNB preparation, although this varied widely.

RT-qPCR was performed to evaluate the presence of host (GAPDH) and viral RNA in both the FNA and MLNB preparations. FCoV RNA was detected in each FNA and MLNB preparation, as was the presence of host-encoded RNA. Overall, slightly higher Ct values were noted for both host and viral genes for the MLN FNA reactions, indicating a lower level of template nucleic acid. MLN FNA FCoV Ct values ranged from 19.4 to 36.1 whereas for MLNB FCoV the range was 18.0 to 28.1, with lower MLNB FCoV Ct values recorded in each of the paired samples. The relationship of FCoV Ct value between sample types is illustrated in Figure 1. For the MLN FNA preparations, a strong negative correlation existed between the GAPDH Ct value and the concentration of total RNA ($r = -0.87, P < 0.01$), as expected. However, only a moderate correlation, which was not statistically significant, existed between the FCoV Ct value and total RNA concentration ($r = -0.61, P = 0.11$), and therefore it could not be concluded that the level of template viral RNA (i.e. viral load) was fully dependent on the concentration of total RNA, the majority of which is host-encoded.

**Viability of RNA in MLN FNAs collected in the field**

As GAPDH RT-qPCR Ct values were shown to strongly correlate with RNA concentration and are dependent on viable host RNA, these values were used as an index for RNA sample quality, in terms of both quantity and intactness. GAPDH Ct
values of 32 MLN FNA samples prepared / collected at the University were compared to twelve samples submitted by mail from external veterinary practices, in order to check for potential RNA deterioration while in transit (supplementary material 2).

The median in-house Ct value was 25.8 while that from external samples was only marginally higher at 28.4 and so it can be concluded that a similarly high level of RNA was found in fresh samples and in those that had been sent by post.

Sensitivity and specificity of the MLN FNA FCoV RT-qPCR assay

FCoV was detected by RT-qPCR in 18 of the 20 cats with non-effusive FIP (Group D). Two extracts contained no detectable FCoV RNA, although both contained ample reference gene RNA, and therefore the test sensitivity was 90 %. Interestingly, these samples represented the only neurological cases of FIP in this group and this association was found to be statistically significant (P = 0.0053, Fishers Exact Test).

FCoV Ct values varied between 22.7 and 38.2 and these showed a moderate correlation with GAPDH Ct values \( (r = 0.72, P < 0.01) \). This relationship is illustrated in Figure 2. Of the 26 cats in the study that did not have FIP (control groups P and N), FCoV was detected in only one cat and thus the overall test specificity was 96.1 %. In practice, an FCoV seronegative status would tend to rule out a diagnosis of FIP and, therefore, this assay has particular relevance to the cohort of non-FIP seropositive cats; the specificity with respect to this group was 87.5 %. The positive sample, with a Ct value of 23, was from cat P04, which was subsequently diagnosed with suppurative bronchopneumonia. Sections from kidney, lung, liver and spleen were analysed by immunohistochemistry but FCoV antigen was not detected in any of the tissues examined. A 2x2 contingency table was generated to evaluate the performance of the MLN FNA RT-qPCR assay compared to standard diagnostic tools for FIP. The
results demonstrated a high inter-rater agreement, which was almost perfect (κ = 0.88; 95 % CI 0.75-1.0).

DISCUSSION

A sensitive, specific and minimally invasive method for supporting or refuting a diagnosis of non-effusive FIP is currently required. A PCR and sequencing based method has recently been developed, which targets a mutated form of FCoV\textsuperscript{7,31,32}.

Although a positive result may be supportive of FIP, the assay suffers from unacceptably low sensitivity (6.5 %) when applied to blood samples\textsuperscript{31} and a recent study concluded that gene mutation analysis does not substantially improve the ability to diagnose FIP as compared to detection of FCoV alone\textsuperscript{32}. This leads to the supposition that an alternative approach, the use of a PCR protocol capable of detecting the virus in a key anatomical site, i.e. mesenteric lymph node tissue, may have more diagnostic utility for suspect cases of non-effusive FIP. Laparotomy for the collection of biopsy material is a potentially stressful and risk-associated intervention. In contrast, sample collection by ultrasound-guided fine-needle aspirate is a far less invasive procedure and therefore an opportunity exists to develop a novel assay for FIP diagnostics using this methodology. While cytology of effusions in FIP is useful in establishing alternative diagnoses such as neoplasia or bacterial peritonitis, cytology of enlarged mesenteric lymph node FNA often provide limited clear diagnostic information, with cytology often described as consistent with reactive hyperplasia (unpublished observation). Norris et al. described reactive hyperplasia in 4/5 cases of confirmed FIP where cytology had been performed on MLN FNA and 1/5 cases as pyogranulomatous inflammation\textsuperscript{33}. In all cases, these observations are non-specific characteristics that are merely suggestive of FIP, and add no solid support. However, a PCR-based assay offers the potential of improved performance
and so the present study set out to investigate whether detecting viral RNA in fine-needle aspirates of MLNs could be used to support a diagnosis of FIP. As a first step, we demonstrated that both host and FCoV RNA can be reliably detected in samples from MLN FNAs as well as in MLNB. The results of the GAPDH RT-qPCR control assay confirmed that sufficient quantities of host RNA can be recovered from MLN FNA samples. Importantly, a very similar level of RNA was recovered from fresh MLN FNA samples prepared in the laboratory and MLN FNA samples which had been collected by submitting veterinary surgeons and sent via the postal system, without any form of preservative. This means that the samples submitted without the use of nucleic preservatives or refrigeration are suitable for use with this assay.

Enlarged MLNs are frequently observed in FIP cases; in all five FIP cases where lymph node size was recorded in the clinical history in the present study, it was described as enlarged. It is from such enlarged MLNs that we would advise taking FNAs. However, if MLNs are of normal size, even using ultrasound guidance, then accessibility and stabilisation of the lymph node are likely the most important factors to allow aspiration of adequate material to test. Other studies suggest sampling from the kidney, and although this organ may be easier to sample, experimental infections provide evidence of lower viral load in these tissues\(^{34}\). Our study, focusing on sampling enlarged MLNs, builds on the work of Kipar \textit{et al.} who detected FCoV viral RNA by RT-PCR in the MLN of 13 of 15 (87 \%) of cats with FIP\(^{35}\). However, as FCoV is primarily an enteric pathogen, its presence in lymph nodes draining the gastrointestinal tract may also be anticipated in FCoV-infected cats without FIP\(^{35}\).

Thus, the study was designed to address two issues: whether in principle RT-qPCR could detect the virus in MLN FNA RNA preparations and, if so, whether it could be a sensitive and specific diagnostic method for FIP investigation.
Samples representing 25 of 26 (96.1%) seronegative or seropositive cats without FIP did not generate a PCR product and thus a diagnosis of FIP was not supported in these cases. FCoV RNA was detected in only one seropositive kitten, P04, which presented with diarrhoea, dyspnoea, a pleural effusion and a highly elevated white cell count. On the basis of histopathology, this cat was subsequently diagnosed with suppurative bronchopneumonia although no bacteria were recovered from the biopsy material. While lesions typical of FIP were not detected by histopathology, the possibility that this cat suffered concurrently from FIP cannot be excluded. This sample demonstrates that FCoV may be detected in the MLN of a small proportion of cats that do not have FIP. Notably, this cat had an intermittent history of diarrhoea, which increased in severity shortly before its death, although it is unknown whether this was FCoV-associated or not. The MLNs are the local draining lymph nodes for the intestinal tract and it is to be expected that at some point during enteric infection by FCoV there will be a transient viral presence in those nodes, following transport by macrophages. It may be hypothesised that, in terms of FIP diagnosis, there is the risk of a false positive result if the animal is tested in this early period of infection. However, it should be appreciated that in practice, this diagnostic test should only be applied when there is a strong index of suspicion of FIP, based on clinical presentation and other laboratory test parameters. This test is not designed to be a screening assay for healthy cats and its application would not be indicated in cases of enteric infection where diarrhoea is the principal clinical sign. However, there remains the potential risk of detecting FCoV in cats experiencing an early FCoV infection, but which have nevertheless been tested because of a concurrent illness, presenting with clinical signs suggestive of FIP. A group of particular concern would be FCoV carrier cats. These individuals are persistently infected with FCoV in the gut and continually shed virus in the faeces, however they
rarely develop FIP\textsuperscript{36}. We can report that MLN biopsy samples from two carrier cats persistently infected with FCoV, collected during the course of a previous study\textsuperscript{37}, were found to be FCoV RNA negative (unpublished data).

In most instances, the first step in FIP diagnosis is to perform haematology, biochemistry and FCoV serology in order to assess the likelihood of the disease. The MLN FNA assay is likely to be most useful in cases where standard non-invasive diagnostic tests produce equivocal results or to further support a diagnosis in cases where FIP is strongly suspected. Eighteen of 20 (90\%) of cases were correctly classified as having FIP by the MLN FNA assay. Two samples, D12 and D13, had been diagnosed histopathologically with neurological FIP and tested negative on FCoV RT-qPCR. This association was found to be statistically significant and was not a wholly unexpected finding. FIP is commonly sub-divided into effusive and non-effusive forms. On the basis of these results, and those of others\textsuperscript{18,38,39}, further classification of non-effusive cases may be useful with respect to determining appropriate diagnostic approaches. In the neurological manifestation of FIP, the virus may have been sequestered in the neural tissues, and thus absent from the MLNs. In one of these two cases, D13, FCoV was detected by RT-qPCR in the CSF. Similarly, in cases of suspected FIP-associated uveitis, the virus may be detected in aqueous humor (unpublished observation). Further data are required in FIP cases with neurological manifestations of FIP, and it is possible that among cases of this type the sensitivity of this assay may be limited. Additionally, further studies with larger numbers of non-FIP, FCoV-seropositive cats are required to more accurately measure the specificity of MLN FNA FCoV RT-qPCR for this presentation of FIP.

The overall sensitivity of the assay was 90\% (FCoV detected in 18 of 20 FIP cases) and the specificity was 96.1\% (FCoV not detected in 25 of 26 controls). Very good
agreement was demonstrated between the MLN FNA assay and the standard diagnostic tools, with an inter-rater agreement (κ) of 0.88. Thus, overall, the results of the study suggest that presence of FCoV in the MLN of systemically ill cats is associated with a diagnosis of FIP. This test, therefore, has value aiding the diagnosis of FIP in cats with a high index of suspicion of disease. This assay is not proposed as a standalone method to diagnose FIP and should be used to complement the standard suite of haematological, biochemical and serological tests currently in use.

**CONCLUSIONS**

The results of this study are encouraging: FCoV RT-qPCR of FNA of the MLN is a useful tool to aid diagnosis of non-effusive FIP. This assay can detect FCoV in MLN FNAs from confirmed FIP cases whilst not detecting FCoV in samples from seronegative cats and the majority of FCoV seropositive cats without FIP. While having limited power to identify neurological cases of FIP, the test is highly sensitive when applied to suspect ‘classic’ systemic FIP cases. As the technique is far less invasive than traditional biopsy and provides useful diagnostic information, it represents a useful addition to the suite of current diagnostic methods for FIP.

**Ethical approval**

The study was approved by the Ethics and Welfare Committee at the University of Glasgow, School of Veterinary Medicine.

**Acknowledgements**

We would like to thank the diagnostic teams within the Veterinary Diagnostic Service at the University of Glasgow for their efforts in the collection and analysis of the samples processed in this study. The authors are grateful to Dr Marina Meli for aiding us in setting up the FCoV RT-qPCR assay. We thank the Angelica Trust for funding
continued FIP research at the University of Glasgow. We are grateful to the John
Robertson Bequest (University of Glasgow) and the BBSRC REP for funding the
studentship of Wendy Kwok. We are grateful to Dr Pablo Nart for perfecting the
protocol for extracting FCoV RNA from tissue samples using the gentle MACS M
tube. Above all, the authors sincerely thank the many people who, despite their grief,
generously donated the body of their deceased pet for post-mortem for this project,
enabling us to eschew the use of experimental cats, and we thank their veterinary
surgeons for sending the pet samples to us.

Funding and conflict of interest

The authors declare no conflict of interests.


Foundation for Statistical Computing, Vienna, Austria. 2013. ISBN 3-900051-07-0,
2014.
30. Nakazawa M and Nakazawa MM. Package ‘fmsb’. Functions for Medical
Statistics Book with some Demographic Data 2017.
gene mutations as a tool to diagnose feline infectious peritonitis. J Feline Med Surg
coronavirus spike protein gene mutations to diagnose feline infectious peritonitis. Vet
Res 2017; 48: 60.
33. Norris JM, Bosward KL, White JD, et al. Clinicopathological findings
associated with feline infectious peritonitis in Sydney, Australia: 42 cases (1990–
and pathological findings in cats experimentally infected with feline coronavirus
exhibit significantly higher viral loads than healthy infected cats. J Feline Med Surg
2006; 8: 69-72.
36. Addie DD and Jarrett O. Use of a reverse-transcriptase polymerase chain
reaction for monitoring the shedding of feline coronavirus by healthy cats. Vet Rec
37. Addie DD, Schaap IAT, Nicolson L, et al. Persistence and transmission of

Table 1: Mesenteric lymph node fine needle aspirate sample source and classification

<table>
<thead>
<tr>
<th>Sample ref</th>
<th>FCoV antibody titre</th>
<th>Sample origin</th>
<th>MLN collection</th>
<th>MLN FNA collection</th>
<th>MLN size</th>
<th>Mass(s) detected (location)</th>
<th>Neurological signs</th>
<th>Ocular signs</th>
<th>Other signs †</th>
<th>Other</th>
<th>Diagnosis</th>
<th>Lesions detected on histology ± IHC confirming FIP</th>
<th>Gross post-mortem lesions highly suggestive of FIP</th>
<th>FIP highly suspected using ABCD guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>D01</td>
<td>&gt;1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>Non-effusive FIP</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D02</td>
<td>&gt;1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>NR</td>
<td>✓ ✓</td>
<td>Non-effusive FIP</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D03</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>Non-effusive FIP</td>
<td>No clinical signs (abnormality detected on routine bloods)</td>
<td>Non-effusive FIP</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D04</td>
<td>&gt;1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>Enlarged</td>
<td>✓</td>
<td>Non-effusive FIP</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D05</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, extra corpus</td>
<td>NR</td>
<td>Abdominal</td>
<td>✓</td>
<td>Non-effusive FIP</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D06</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>Enlarged</td>
<td>✓</td>
<td>Non-effusive FIP</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D07</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>Enlarged</td>
<td>✓</td>
<td>Non-effusive FIP</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D08</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D09</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>NR</td>
<td>Abdominal</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D10</td>
<td>1:1280</td>
<td>Field</td>
<td>Post mortem, extra corpus</td>
<td>Enlarged</td>
<td>✓</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D11</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Post mortem, extra corpus</td>
<td>NR</td>
<td>✓</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D12</td>
<td>&gt;1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>✓</td>
<td>Neurological FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D13</td>
<td>1:640</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Neurological FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D14</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D15</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>Non- effusive FIP &amp; toxoplasmosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>Enlarged MLN</td>
<td>✓</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D17</td>
<td>&gt;1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D18</td>
<td>1:320</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>NR</td>
<td>✓</td>
<td>Non- effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D19</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Post mortem, extra corpus</td>
<td>NR</td>
<td>No clinical signs (abnormality detected on)</td>
<td>Non- effusive FIP</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GROUP</td>
<td>dilution</td>
<td>location</td>
<td>histological findings</td>
<td>routine bloods</td>
<td>diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>----------</td>
<td>-----------------------</td>
<td>-----------------</td>
<td>-----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D20</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td></td>
<td>Non-effusive FIP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P01</td>
<td>1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>Enlarged MLN</td>
<td>Toxocara infestation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P02</td>
<td>1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>Enlarged</td>
<td>NAD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P03</td>
<td>&gt;1:1280</td>
<td>UniPM</td>
<td>Post mortem, in situ</td>
<td>Enlarged</td>
<td>Nutritional hyperparathyroidism leading to osteopenia. Possible osteogenesis imperfecta.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P04</td>
<td>1:1280</td>
<td>Field</td>
<td>Post mortem, extra corpus</td>
<td>Enlarged</td>
<td>Respiratory signs</td>
<td>Suppurative bronchopneumonia (bacterial culture negative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P05</td>
<td>1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>Enlarged</td>
<td>Lymphocytic plasmacytic enteritis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P06</td>
<td>&gt;1:1280</td>
<td>Field</td>
<td>Ante-mortem, in situ</td>
<td>Not enlarged</td>
<td>Healthy</td>
<td>Survived 12 months post-testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P07</td>
<td>1:320</td>
<td>Field</td>
<td>Post mortem, extra corpus</td>
<td>Not enlarged</td>
<td>Trauma</td>
<td>Suspected RTA/ trauma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P08</td>
<td>1:40</td>
<td>Field</td>
<td>Post mortem, extra corpus</td>
<td>Enlarged</td>
<td>Acute myeloid leukaemia and secondary gastric</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Group P - FCoV seropositive non-FIP control cases (n = 8)**
<table>
<thead>
<tr>
<th>No.</th>
<th>titer</th>
<th>Laboratory</th>
<th>Case Details</th>
<th>Gross Pathological Findings</th>
<th>Radiological Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>N01</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, Not enlarged</td>
<td>✓</td>
<td>Signs of inflammatory process in neural tissues, Borna virus infection suspected</td>
</tr>
<tr>
<td>N02</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, Tumour ear</td>
<td></td>
<td>Shelter cat, teaching case</td>
</tr>
<tr>
<td>N03</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, teaching case</td>
</tr>
<tr>
<td>N04</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, teaching case</td>
</tr>
<tr>
<td>N05</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, teaching case</td>
</tr>
<tr>
<td>N06</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, trauma</td>
</tr>
<tr>
<td>N07</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, teaching case</td>
</tr>
<tr>
<td>N08</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, teaching case</td>
</tr>
<tr>
<td>N09</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, teaching case</td>
</tr>
<tr>
<td>N10</td>
<td>&lt;1:10</td>
<td>UniPM</td>
<td>Post mortem, in situ, NR</td>
<td></td>
<td>Shelter cat, spinal deformity</td>
</tr>
</tbody>
</table>

Group N - FCoV seronegative non-FIP control cases (n = 18)
| N11 | <1:10 | Field | Ante-mortem, in situ | Enlarged | ✓ | Survived greater than 4 months post-testing |  
| N12 | <1:10 | UniPM | Post mortem, in situ | Not enlarged | | Trauma | Head trauma |  
| N13 | <1:10 | UniPM | Post mortem, in situ | Not enlarged | | Shelter cat, FIV positive |  
| N14 | <1:10 | UniPM | Post mortem, in situ | Enlarged | ✓ | Foreign body in jejunum; early carcinoma in the lung with secondary pneumonia. |  
| N15 | <1:10 | UniPM | Post mortem, in situ | Not enlarged | | Respiratory signs | Pneumonia and concurrent bacterial infection |  
| N16 | <1:10 | UniPM | Post mortem, in situ | Not enlarged | | Found dead after missing 2 days | Trauma likely due to road accident |  
| N17 | <1:10 | Field | Post mortem | | | Abdominal | NAD |  
| N18 | <1:10 | UniPM | Post mortem, in situ | Not enlarged | ✓ | Intussusception, string foreign body, supplicative peritonitis. |
Field: MLNB or MLN FNA collected by referring veterinary surgeon

UniPM: MLN FNA collected by University of Glasgow pathologist

NR: Not recorded

NAD: No abnormality detected

† Non-specific signs including but was not limited to pyrexia, lethargy, inappetence and icterus

✓: clinical sign present / test results support a diagnosis of FIP

✗: test results do not support a diagnosis of FIP

IHC: immunohistochemistry
Table 2: Primers and probes sequences used in the RT-PCR assay

<table>
<thead>
<tr>
<th>Target Gene</th>
<th>Primer or Probe</th>
<th>Sequence (5' → 3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCoV 7b gene*</td>
<td>Forward primer</td>
<td>GAT TTG ATT TGG CAA TGC TAG ATT T</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>AAC AAT CAC TAG ATC CAG ACG TTA GCT</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>TCC ATT GTT GGC TCG TCA TAG CGG A</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward primer</td>
<td>GCC GTG GAA TTT GCC GT</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>GCC ATC AAT GAC CCC TTC AT</td>
</tr>
<tr>
<td></td>
<td>Probe</td>
<td>CTC AAC TAC ATG GTC TAC ATG TTC CAG TAT GAT TCCA</td>
</tr>
</tbody>
</table>

*Designed by Gut et al. (1999) to amplify the FCoV 7b gene
Figure 1. Bar chart illustrating the relationship between FCoV RT-qPCR Ct values from matched mesenteric lymph node biopsy (MLNB) and fine-needle aspirate (FNA) samples. The Ct values from MLNBs were generally lower than those from MLNs, indicating higher virus loads in the MLNB pieces than in FNAs. However, three samples produced MLNB and MLN FNA Ct values which were almost identical.
Figure 2. Relationship between FCoV and GAPDH Ct values for non-effusive FIP samples where FCoV was detected. A moderate positive correlation ($r = 0.72$, $P < 0.01$) was detected between Ct values of the ‘test’ gene, FCoV, and the reference host control gene, GAPDH. Thus, broadly, the lower level of host RNA detected, the lower level of FCoV detected.